Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMABNASDAQ:MNPRNASDAQ:SCPHNASDAQ:TYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMABI-Mab$2.50+7.3%$1.35$0.60▼$3.08$204.15M1.17363,432 shs368,899 shsMNPRMonopar Therapeutics$32.86-0.4%$37.30$1.72▼$54.30$200.95M0.99359,293 shs21,168 shsSCPHscPharmaceuticals$3.84-2.0%$3.17$1.94▼$5.65$202.72M0.36371,517 shs454,814 shsTYMETyme Technologies$0.31$0.30$0.22▼$1.14$53.51M0.931.01 million shs2.68 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMABI-Mab+7.30%+0.40%+165.06%+193.91%+41.24%MNPRMonopar Therapeutics-0.42%-1.97%-7.59%-17.85%+694.68%SCPHscPharmaceuticals-2.04%-2.78%+14.97%+28.00%-3.76%TYMETyme Technologies0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMABI-Mab2.216 of 5 stars3.74.00.00.00.61.70.0MNPRMonopar Therapeutics2.8901 of 5 stars3.45.00.00.00.02.50.0SCPHscPharmaceuticals4.1158 of 5 stars3.54.00.04.21.11.70.6TYMETyme TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMABI-Mab 3.33Buy$5.50120.00% UpsideMNPRMonopar Therapeutics 2.75Moderate Buy$55.3368.39% UpsideSCPHscPharmaceuticals 3.00Buy$14.00264.58% UpsideTYMETyme Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TYME, SCPH, IMAB, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/4/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/2/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMABI-Mab$3.89M52.48N/AN/A$2.47 per share1.01MNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ASCPHscPharmaceuticals$36.33M5.58N/AN/A$0.27 per share14.22TYMETyme TechnologiesN/AN/AN/AN/A$0.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)SCPHscPharmaceuticals-$85.15M-$1.91N/AN/AN/A-216.24%-594.07%-73.54%8/13/2025 (Estimated)TYMETyme Technologies-$23.63M-$0.14N/A∞N/AN/A-28.30%-26.21%N/ALatest TYME, SCPH, IMAB, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A3/31/2025Q4 2024MNPRMonopar Therapeutics-$0.36-$2.23-$1.87-$2.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMABI-MabN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ATYMETyme TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMABI-MabN/A22.3522.35MNPRMonopar TherapeuticsN/A36.9136.91SCPHscPharmaceuticals3.865.484.61TYMETyme TechnologiesN/A14.0614.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMABI-Mab38.38%MNPRMonopar Therapeutics1.83%SCPHscPharmaceuticals89.52%TYMETyme Technologies16.69%Insider OwnershipCompanyInsider OwnershipIMABI-Mab22.10%MNPRMonopar Therapeutics20.50%SCPHscPharmaceuticals4.78%TYMETyme Technologies16.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMABI-Mab38081.66 million63.61 millionOptionableMNPRMonopar Therapeutics106.12 million4.86 millionNot OptionableSCPHscPharmaceuticals3052.79 million50.27 millionOptionableTYMETyme Technologies17172.21 million143.10 millionOptionableTYME, SCPH, IMAB, and MNPR HeadlinesRecent News About These CompaniesTyme caps off a tough year for African startups with a unicorn crownJanuary 12, 2025 | independent.co.ugHow Nubank’s Investment in Tyme Helps African StartupsJanuary 8, 2025 | fintechmagazine.comNubank leads Tyme Group’s $250m Series D – valuing Tyme at $1.5bnJanuary 3, 2025 | intelligentcio.comTyme é avaliado em US$ 1,5 bi com apoio do Nubank, na ÁfricaDecember 18, 2024 | bloomberg.comBrazil’s Nubank invests $150 million in Tyme Group to expand digital banking offeringsDecember 18, 2024 | msn.comBrazilian bank Nubank makes a big R2.7bn investment in fintech Tyme GroupDecember 18, 2024 | msn.comSouth African Tyme Group Becomes Africa’s Latest Unicorn After $250M Series D FundingDecember 18, 2024 | msn.comTymeBank parent valued at $1.5-billion in latest fundraiseDecember 17, 2024 | techcentral.co.zaBrazilian fintech giant invests in SA-born Tyme GroupDecember 17, 2024 | itnewsafrica.comMulti-billion funding bolsters Tyme Group valuationDecember 17, 2024 | itweb.co.zaBillionaire Patrice Motsepe’s Tyme worth $1.5 billion becomes Africa’s 9th unicornDecember 17, 2024 | nairametrics.comTyme, Owners Of TymeBank And GoTyme, Raises R4.5 Billion In Funding Led By NYSE-Listed Brazilian FinTech NubankDecember 17, 2024 | techfinancials.co.zaBrazilian fintech Nubank’s $150mn investment to give South Africa’s Tyme unicorn statusDecember 17, 2024 | ft.comAfrican digital bank Tyme raises $250M round led by Nubank at $1.5B valuationDecember 17, 2024 | msn.comDigital bank Tyme gains unicorn status with $250m Series D raiseDecember 17, 2024 | finance.yahoo.comNubank Announces Investment in Tyme Group, a Digital Bank With Operations in South Africa and the PhilippinesDecember 16, 2024 | businesswire.comBest Restaurants in Leominster, MassachusettsNovember 10, 2024 | thetechedvocate.orgBest Restaurants in Quincy, IllinoisNovember 10, 2024 | thetechedvocate.orgBest Restaurants in Peoria, IllinoisNovember 9, 2024 | thetechedvocate.orgEden Green herb program named on TIME’s Best Inventions of 2024 listNovember 6, 2024 | producegrower.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTYME, SCPH, IMAB, and MNPR Company DescriptionsI-Mab NASDAQ:IMAB$2.50 +0.17 (+7.30%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.42 -0.08 (-3.00%) As of 06/20/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Monopar Therapeutics NASDAQ:MNPR$32.86 -0.14 (-0.42%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$32.87 +0.01 (+0.03%) As of 06/20/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.scPharmaceuticals NASDAQ:SCPH$3.84 -0.08 (-2.04%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.86 +0.02 (+0.39%) As of 06/20/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Tyme Technologies NASDAQ:TYMETyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
